Levamisole, the story and the lessons
1Janssen Research Foundation, Beerse, Belgium.
International Journal of Immunopharmacology
|April 1, 1992
Summary
Levamisole, initially an anthelmintic, has evolved into an important immunotropic agent. Recent trials highlight its effectiveness as an adjuvant treatment for operable colon cancer, underscoring its enduring role in cancer therapy.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Levamisole's historical trajectory spans from anthelmintic use to immunomodulation.
- Its clinical significance resurged with adjuvant therapy for colon cancer.
Purpose of the Study:
- To review the historical use and evolving applications of levamisole.
- To synthesize evidence from experimental models and clinical trials in cancer treatment.
Main Methods:
- Literature review of levamisole's history and applications.
- Analysis of experimental tumor models and clinical data.
- Evaluation of large-scale controlled trials in resectable colon cancer.
Main Results:
- Levamisole demonstrated efficacy as an adjuvant treatment for operable colon cancer.
- Evidence from diverse cancer types and experimental models supports its immunotropic properties.
Conclusions:
- Levamisole remains a significant therapeutic agent, particularly in adjuvant colon cancer treatment.
- The study emphasizes the role of serendipity in drug discovery and development.
Related Concept Videos
01:29Life Histories
Constrained by limited energy and resources, organisms must compromise between offspring quantity and parental investment. This trade-off is represented by two primary reproductive strategies; K-strategists produce few offspring but provide substantial parental support, whereas r-strategists produce much progeny that receives little care. These strategies are related to an organism’s survival likelihood across its lifespan, which is represented by a survivorship curve. Three general types of...
01:26Pharmaceutical Poisoning: Treatment Strategies
Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
01:30Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
01:28Amebiasis
Entamoeba histolytica, a protozoan parasite, is responsible for intestinal and extraintestinal amebiasis. Though a significant proportion of infections remain asymptomatic, approximately 50 million individuals annually are estimated to present with clinical disease, resulting in up to 100,000 deaths globally. The disease burden is disproportionately high in regions with lower socioeconomic status, such as parts of India, Africa, Mexico, and Latin America.Etiology and TransmissionThe infective...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...